Journey Medical (NASDAQ:DERM) Earns Buy Rating from Analysts at Roth Mkm

Roth Mkm began coverage on shares of Journey Medical (NASDAQ:DERM) in a research report report published on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $11.00 price target on the stock.

Journey Medical Price Performance

Journey Medical stock opened at $5.64 on Friday. Journey Medical has a fifty-two week low of $1.52 and a fifty-two week high of $8.11. The company has a quick ratio of 0.94, a current ratio of 1.21 and a debt-to-equity ratio of 1.13. The company has a market cap of $112.86 million, a price-to-earnings ratio of -18.19 and a beta of 0.79. The business’s 50 day moving average price is $4.20.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.27). The firm had revenue of $13.03 million during the quarter, compared to analyst estimates of $14.91 million. Journey Medical had a negative net margin of 5.20% and a negative return on equity of 32.83%. As a group, analysts predict that Journey Medical will post -1.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Journey Medical

Several institutional investors have recently modified their holdings of DERM. Acadian Asset Management LLC increased its stake in Journey Medical by 687.5% during the 1st quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after purchasing an additional 194,389 shares in the last quarter. Heron Bay Capital Management acquired a new position in shares of Journey Medical in the first quarter valued at approximately $124,000. Finally, Nwam LLC bought a new stake in shares of Journey Medical during the first quarter worth $41,000. Institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.